

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY COSTA RICA	2. DATE OF BIRTH			2a. AGE 78 Years	3. SEX Female	3a. WEIGHT Unk	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING
		Day	Month	Year				Day	Month	Year	
			PRIVACY						APR	2025	

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)
 Terrible arm pain [Pain in arm]
 A lot of cramps in her feet [Foot cramps]
 Cough [Cough]
 Her defenses were a little low/Low defenses [Decreased immune responsiveness]
 Blood pressure was a little low/It was going down a little and then it was going up [Blood pressure fluctuation]
 Blisters appeared in her heel [Blisters]
 In her toes, her skin was thick [Skin thickening]

(Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) Ibrance (PALBOCICLIB) Capsule (Lot # SK751; Exp.Dt. 31-JUL-2027) #2) ARIMIDEX (ANASTROZOLE)		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1) Daily, 21 days on, 7 days off #2) UNK	16. ROUTE(S) OF ADMINISTRATION #1) Unknown #2) Unknown	
17. INDICATION(S) FOR USE #1) Unknown #2) Unknown		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) Unknown #2) Unknown	19. THERAPY DURATION #1) Unknown #2) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates	Type of History / Notes	Description
Unknown	Relevant Med History	Breast operation NOS (Breast operation)
Unknown	Relevant Med History	Hyperaesthesia (Hyperaesthesia)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San Jose, COSTA RICA		26. REMARKS
	24b. MFR CONTROL NO. PV202500056646	
24c. DATE RECEIVED BY MANUFACTURER 19-MAY-2025	24d. REPORT SOURCE <input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input checked="" type="checkbox"/> OTHER: Spontaneous	
DATE OF THIS REPORT 22-MAY-2025	25a. REPORT TYPE <input type="checkbox"/> INITIAL <input checked="" type="checkbox"/> FOLLOWUP: 1	
		25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD.

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

Case Description: This is a spontaneous report received from a Consumer or other non-HCP, Program ID: 164974.

A 78-year-old female patient received palbociclib (IBRANCE), (Lot number: SK751, Expiration Date: 31Jul2027) at 125 mg cyclic (daily, 21 days on, 7 days off); anastrozole (ARIMIDEX). The patient's relevant medical history included: "Breast surgery" (unspecified if ongoing); "Her arm was more sensitive" (unspecified if ongoing); "Terrible pain" (unspecified if ongoing); "Eye operation (glaucoma)" (unspecified if ongoing); "Susceptible to suffer from the pressure" (unspecified if ongoing). The patient's concomitant medications were not reported.

The following information was reported: DECREASED IMMUNE RESPONSIVENESS (non-serious) with onset Apr2025, outcome "unknown", described as "Her defenses were a little low/Low defenses"; PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "Terrible arm pain"; MUSCLE SPASMS (non-serious), outcome "unknown", described as "A lot of cramps in her feet"; COUGH (non-serious), outcome "unknown"; BLOOD PRESSURE FLUCTUATION (non-serious), outcome "unknown", described as "Blood pressure was a little low/It was going down a little and then it was going up"; BLISTER (non-serious), outcome "recovering", described as "Blisters appeared in her heel"; SKIN HYPERTROPHY (non-serious), outcome "recovering", described as "In her toes, her skin was thick". The action taken for anastrozole was unknown; for palbociclib was temporarily withdrawn. Therapeutic measures were taken as a result of blister, skin hypertrophy.

Additional information: The patient reported that she realized that the other one was called "Arimidex". It was the one that was giving to her, and it caused great pain in an arm and foot cramps. Nevertheless, she realized that she had always been given Palbociclib and Arimidex together. She reported that she had taken it. She had surgery on her chest (breast surgery), on one side. Her arm was more sensitive, so she had terrible pain. The patient reported that she did not take the treatment for a month. That was when she realized that the cramps and pain in her arm went away. As of 19May2025, the patient reported that she was taking Ibrance, and her defenses were a little low. She had to suspend the treatment about a month ago. In addition, the patient's blood pressure was a little low, she was susceptible to suffer from the pressure, but it was going down a little and then it was going up. The patient indicated that she was also worried because one of her children was going to undergo surgery. The patient had one eye operated for glaucoma, and she would have to operate the other eye. She did not know if she would be able to operate since she had low defenses. The patient indicated that the treatment caused an effect on her skin, blisters appeared in her heel, and in her toes, her skin was thick. The patient had been given a cream, and it did her very good. Finally, the patient reported that it was very difficult for her to remove the capsule, it was very difficult for her to open the box of the medication. The patient indicated that she was elderly, and she was poor, she had low income.

Follow-up (19May2025): This is a spontaneous follow-up report received from a Consumer or other non-HCP, Program ID: 164974. Updated information: Correspondence contact profession updated. New relevant medical history. Dosage regimen and drug expiration date were updated. The action taken for palbociclib has been updated (from unknown to temporarily withdrawn). New events of "Decreased immune responsiveness", "Blood pressure fluctuation", "Blisters", "Skin thickening", and clinical course updated.

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
Unknown	Relevant Med History	Pain (Pain);
Unknown	Relevant Med History	Glaucoma surgery (Glaucoma surgery);
Unknown	Relevant Med History	Blood pressure abnormal (Blood pressure abnormal);